(Q49049736)

English

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

scientific article published in March 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. (English)

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

author name string

Filip Van Den Bosch

1

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Elli Kruithof

2

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Dominique Baeten

3

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Annemie Herssens

4

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Filip de Keyser

5

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Herman Mielants

6

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Eric M Veys

7

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

publication date

1 March 2002

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Arthritis & Rheumatology

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

46

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

3

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

755-765

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

Seronegative polyarthritis: a unified concept

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

CONTROLLED TRIAL OF SULPHASALAZINE IN THE TREATMENT OF ULCERATIVE COLITIS.

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Methotrexate use in psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study

1 reference

https://api.crossref.org/works/10.1002%2FART.511

21 January 2018

Identifiers

10.1002/ART.511

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/11920412

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49049736&oldid=2120757091"